Imugene to Host Webinar on Azer-cel Phase 1b Trial Data

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.Imugene ( (AU:IMU) ) just unveiled an update. Imugene Limited announced a webinar to present the latest data from its Phase 1b trial of the azer-cel drug. The webinar, hosted by key company executives, is an opportunity for shareholders and investors to gain insights into the progress of this promising therapy. This event underscores Imugene’s commitment to transparency and stakeholder engagement as it advances its innovative cancer treatment pipeline. The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page. More about Imugene Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies designed to activate the immune system of cancer patients to target and eliminate tumors. The company’s pipeline includes an allogeneic cell therapy CAR T drug, azer-cel, targeting CD19 for blood cancers, and oncolytic virotherapy aimed at various cancers. Imugene aims to transform cancer treatment and improve patient outcomes, supported by a team of international cancer experts. Average Trading Volume: 558,515 Technical Sentiment Signal: Sell Current Market Cap: A$93.35M Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page. Trending Articles:Can Amazon Gain 35%? Top Analyst Cites Improving Macro Backdrop and AWS Strength Tesla Price Target Trimmed by Top Analyst Despite Improving U.S. Auto Outlook 3 “Strong Buy” Technology Stocks to Buy Now, 7/11/25, According to Top AnalystsDisclaimer & DisclosureReport an Issue